Equities Analysts Offer Predictions for APLS Q1 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a report released on Monday, March 3rd. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.47) per share for the quarter, up from their prior estimate of ($0.55). HC Wainwright has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.41) EPS and FY2027 earnings at $0.95 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. The company had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.73) earnings per share.

APLS has been the subject of several other reports. Wedbush decreased their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Monday. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Citigroup lowered their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. JPMorgan Chase & Co. increased their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Morgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.53.

Apellis Pharmaceuticals Price Performance

APLS stock opened at $25.05 on Wednesday. The stock has a 50-day moving average price of $29.53 and a two-hundred day moving average price of $31.30. Apellis Pharmaceuticals has a 1 year low of $23.77 and a 1 year high of $64.58. The stock has a market cap of $3.12 billion, a PE ratio of -12.34 and a beta of 0.93. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares during the period. Wolverine Asset Management LLC acquired a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. True Wealth Design LLC acquired a new stake in Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. Signaturefd LLC boosted its stake in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares during the period. Finally, Capital Performance Advisors LLP acquired a new position in Apellis Pharmaceuticals in the 3rd quarter valued at $56,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Activity

In related news, CEO Cedric Francois sold 13,551 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $412,356.93. Following the sale, the chief executive officer now owns 418,519 shares in the company, valued at approximately $12,735,533.17. This represents a 3.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00. Following the transaction, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at approximately $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 60,365 shares of company stock valued at $1,810,479 over the last three months. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).